Karjalainen A, Witalisz-Siepracka A, Prchal-Murphy M, Martin D, Sternberg F, Krunic M
Cell Mol Life Sci. 2025; 82(1):98.
PMID: 40025196
PMC: 11872851.
DOI: 10.1007/s00018-025-05625-9.
Bieniussa L, Stolte C, Arampatzi P, Engert J, Volker J, Hagen R
Front Mol Neurosci. 2024; 17:1455136.
PMID: 39469187
PMC: 11513353.
DOI: 10.3389/fnmol.2024.1455136.
Xie Q, Wang J, Li R, Liu H, Zhong Y, Xu Q
Int J Biol Sci. 2024; 20(11):4222-4237.
PMID: 39247821
PMC: 11379073.
DOI: 10.7150/ijbs.99511.
Karim A, Garg R, Saikia B, Tiwari A, Sahu S, Malhotra M
Front Immunol. 2024; 15:1332817.
PMID: 39229272
PMC: 11369709.
DOI: 10.3389/fimmu.2024.1332817.
Lin J, Ge M, Liu C, Holewinski R, Andresson T, Yu Z
Nat Commun. 2024; 15(1):7372.
PMID: 39191751
PMC: 11349758.
DOI: 10.1038/s41467-024-50925-6.
NRN1 interacts with Notch to increase oncogenic STAT3 signaling in melanoma.
Devitt L, Westphal D, Pieger K, Schneider N, Bosserhoff A, Kuphal S
Cell Commun Signal. 2024; 22(1):256.
PMID: 38705997
PMC: 11071257.
DOI: 10.1186/s12964-024-01632-8.
Structural determinants of mitochondrial STAT3 targeting and function.
Marie I, Lahiri T, Onder O, Elenitoba-Johnson K, Levy D
Mitochondrial Commun. 2024; 2:1-13.
PMID: 38500969
PMC: 10947224.
DOI: 10.1016/j.mitoco.2024.01.001.
Signal Transducer and Activator of Transcription Proteins at the Nexus of Immunodeficiency, Autoimmunity and Cancer.
Liongue C, Sobah M, Ward A
Biomedicines. 2024; 12(1).
PMID: 38255152
PMC: 10813391.
DOI: 10.3390/biomedicines12010045.
Chromosomal instability and inflammation: a catch-22 for cancer cells.
van den Brink A, Suarez Peredo Rodriguez M, Foijer F
Chromosome Res. 2023; 31(3):19.
PMID: 37561163
PMC: 10415485.
DOI: 10.1007/s10577-023-09730-y.
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms.
Grockowiak E, Korn C, Rak J, Lysenko V, Hallou A, Panvini F
Nat Cancer. 2023; 4(8):1193-1209.
PMID: 37550517
PMC: 10447237.
DOI: 10.1038/s43018-023-00607-x.
Strategies to therapeutically modulate cytokine action.
Leonard W, Lin J
Nat Rev Drug Discov. 2023; 22(10):827-854.
PMID: 37542128
DOI: 10.1038/s41573-023-00746-x.
JAKs and STATs from a Clinical Perspective: Loss-of-Function Mutations, Gain-of-Function Mutations, and Their Multidimensional Consequences.
Ott N, Faletti L, Heeg M, Andreani V, Grimbacher B
J Clin Immunol. 2023; 43(6):1326-1359.
PMID: 37140667
PMC: 10354173.
DOI: 10.1007/s10875-023-01483-x.
PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy.
Kelm J, Pandey D, Malin E, Kansou H, Arora S, Kumar R
Mol Cancer. 2023; 22(1):62.
PMID: 36991452
PMC: 10061819.
DOI: 10.1186/s12943-022-01707-5.
Prolactin levels and breast cancer risk by tumor expression of prolactin-related markers.
Hathaway C, Rice M, Collins L, Chen D, Frank D, Walker S
Breast Cancer Res. 2023; 25(1):24.
PMID: 36882838
PMC: 9990334.
DOI: 10.1186/s13058-023-01618-3.
An overview of PROTACs: a promising drug discovery paradigm.
Liu Z, Hu M, Yang Y, Du C, Zhou H, Liu C
Mol Biomed. 2022; 3(1):46.
PMID: 36536188
PMC: 9763089.
DOI: 10.1186/s43556-022-00112-0.
STAT3 potentiates RNA polymerase I-directed transcription and tumor growth by activating RPA34 expression.
Zhang C, Wang J, Song X, Yu D, Guo B, Pang Y
Br J Cancer. 2022; 128(5):766-782.
PMID: 36526675
PMC: 9977892.
DOI: 10.1038/s41416-022-02098-6.
The JAK-STAT Signaling Pathway in Epilepsy.
Sun H, Ma D, Cheng Y, Li J, Zhang W, Jiang T
Curr Neuropharmacol. 2022; 21(10):2049-2069.
PMID: 36518035
PMC: 10556373.
DOI: 10.2174/1570159X21666221214170234.
Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer.
Jin J, Wu Y, Zhao Z, Wu Y, Zhou Y, Liu S
JCI Insight. 2022; 7(22).
PMID: 36509291
PMC: 9746828.
DOI: 10.1172/jci.insight.160606.
Differential HLA class I subunit (A, B, C heavy chain and β-microglobulin) expression levels in normal tissues.
Ugolini F, Szumera-Cieckiewicz A, Baroni G, Nesi G, Mandala M, Ferrone S
Virchows Arch. 2022; 482(2):359-368.
PMID: 36437414
PMC: 9931818.
DOI: 10.1007/s00428-022-03459-5.
Recent Advances in PROTACs for Drug Targeted Protein Research.
Yao T, Xiao H, Wang H, Xu X
Int J Mol Sci. 2022; 23(18).
PMID: 36142231
PMC: 9499226.
DOI: 10.3390/ijms231810328.